Iloprost

Iloprost
Clinical data
Trade names	Ventavis, Ilomedine, Aurlumyn
AHFS/Drugs.com	Monograph
MedlinePlus	a612032
License data	US DailyMed: Iloprost;
Routes of; administration	Inhalation, intravenous
ATC code	B01AC11 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	60%
Metabolism	Via β-oxidation to inactive tetranor-iloprost
Elimination half-life	20–30 minutes
Excretion	Kidney (68%) and fecal (12%)
Identifiers
	IUPAC name 5-{(E)-(1S,5S,6R,7R)-7-hydroxy-6[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid;
CAS Number	78919-13-8 73873-87-7;
PubChem CID	5311181;
DrugBank	DB01088 ;
ChemSpider	4470703 ;
UNII	JED5K35YGL;
KEGG	D02721 ;
ChEMBL	ChEMBL236025 ;
CompTox Dashboard (EPA)	DTXSID2041046 ;
ECHA InfoCard	100.163.887
Chemical and physical data
Formula	C22H32O4
Molar mass	360.494 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O;
	InChI InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 ; Key:HIFJCPQKFCZDDL-ACWOEMLNSA-N ;
	(what is this?) (verify)

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues.^[4] Iloprost is a prostacyclin mimetic.^[1]

For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.

^ ^a ^b ^c ^d ^e ^f ^g "Ventavis- iloprost solution". DailyMed. 26 July 2022. Archived from the original on 19 February 2024. Retrieved 19 February 2024.
^ "Aurlumyn- iloprost injection, solution". DailyMed. 11 March 2024. Retrieved 6 May 2024.
^ "Ventavis EPAR". European Medicines Agency (EMA). 26 August 2013. Archived from the original on 12 November 2020. Retrieved 19 February 2024.
^ "Iloprost Information" (PDF). Archived from the original (PDF) on 6 April 2016. Retrieved 5 February 2009.

[Ventavis_FDA_label-1] ^ ^a ^b ^c ^d ^e ^f ^g "Ventavis- iloprost solution". DailyMed. 26 July 2022. Archived from the original on 19 February 2024. Retrieved 19 February 2024.

[Aurlumyn_FDA_label-2] "Aurlumyn- iloprost injection, solution". DailyMed. 11 March 2024. Retrieved 6 May 2024.

[Ventavis_EPAR-3] "Ventavis EPAR". European Medicines Agency (EMA). 26 August 2013. Archived from the original on 12 November 2020. Retrieved 19 February 2024.

[autogenerated1-4] "Iloprost Information" (PDF). Archived from the original (PDF) on 6 April 2016. Retrieved 5 February 2009.

[1]

[2]

[3]

[4]